Literature DB >> 6765416

Comparative pharmacokinetics of ceftazidime and moxalactam.

T B Tjandramaga, A Van Hecken, A Mullie, R Verbesselt, P J De Schepper, L Verbist.   

Abstract

The pharmacokinetics of ceftazidime and moxalactam were compared after intravenous and intramuscular administration of single 1-g doses to eight healthy volunteers in a crossover study. The bioavailability of the antibiotics after administration by either route was almost complete. Both drugs had similar areas under the serum curves. Significant differences between ceftazidime and moxalactam were observed with respect to the apparent volume of distribution (18.4 and 24.1 liters, respectively), to the terminal half-life (1.6 versus 2.0 h), and to urinary recovery of the active compound (96 versus 79%). Ceftazidime was almost completely eliminated by renal excretion (greater than 96%), whereas about 20% of the moxalactam was eliminated by nonrenal mechanisms. The concentrations of ceftazidime and moxalactam in serum after a 1-g dose exceeded the concentrations required to inhibit 90% of the Enterobacteriaceae for about 8 and 10 h, respectively. The levels of ceftazidime and moxalactam in serum exceeded the 90% minimal inhibitory concentration of Pseudomonas aeruginosa for about 6 and 1 h, respectively.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6765416      PMCID: PMC183718          DOI: 10.1128/AAC.22.2.237

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

2.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

3.  Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

Authors:  S Srinivasan; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.

Authors:  R Wise; S Baker; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

6.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

7.  Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.

Authors:  T B Tjandramaga; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

9.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

10.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  16 in total

1.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

2.  Pharmacokinetics of ceftazidime in normal and uremic subjects.

Authors:  A Leroy; F Leguy; F Borsa; G R Spencer; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

3.  Effect of decreased renal function on the pharmacokinetics of ceftazidime.

Authors:  B H Ackerman; J Ross; R W Tofte; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  Pharmacokinetics of ceftazidime in male and female volunteers.

Authors:  D K Sommers; L Walters; M Van Wyk; S M Harding; A M Paton; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 5.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

7.  Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.

Authors:  J W Mouton; A M Horrevorts; P G Mulder; E P Prens; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

8.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

9.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.